S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02%

Next Bullish Trade

Sign in

Account

Create free accountFree dashboard, no payment Sign inEmail yourself a login link CoursesYour library & catalog

BMY

Bristol-Myers Squibb Company NYQ · BMY

$60.74 +0.23 (+0.38%)

Extended · +1.79σ Grade C

+ Compare Open in Sniper

News · BMY

Full news feed →

IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?

The Motley Fool · 3h ago

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

GlobeNewswire Inc. · 3d ago

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

GlobeNewswire Inc. · 5d ago

2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now

The Motley Fool · 11d ago

Exploring the Cancer Metabolism-Based Therapeutics Market: Key Drivers and Challenges to $26.3 Billion Growth

GlobeNewswire Inc. · 15d ago

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 22d ago

Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

GlobeNewswire Inc. · 25d ago

Should You Buy Moderna Before Aug. 5?

The Motley Fool · 26d ago

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

GlobeNewswire Inc. · 26d ago

Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook

The Motley Fool · 30d ago

3 Dividend Stocks to Hold for the Long Haul

The Motley Fool · 32d ago

How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.

The Motley Fool · 35d ago

Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.

The Motley Fool · 37d ago

Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med

Benzinga · 37d ago

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

GlobeNewswire Inc. · 38d ago

Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?

The Motley Fool · 44d ago

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 46d ago

Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks

The Motley Fool · 47d ago

CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking

The Motley Fool · 47d ago

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

The Motley Fool · 48d ago

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

GlobeNewswire Inc. · 49d ago

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

GlobeNewswire Inc. · 57d ago

BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung

GlobeNewswire Inc. · 57d ago

The Most Undervalued Healthcare Stock in the S&P 500 Right Now

The Motley Fool · 58d ago

Anthropic And OpenAI--Building Different Competitive Advantages

Benzinga · 59d ago